Thorax

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH REGISTER
[Advanced]

Thorax. Published Online First: 17 January 2008. doi:10.1136/thx.2007.087155
Copyright © 2008 BMJ Publishing Group Ltd & British Thoracic Society

This Article
Right arrow Full Text (Rapid PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Cheng, S.-L.
Right arrow Articles by Yang, P.-C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cheng, S.-L.
Right arrow Articles by Yang, P.-C.

Papers

Increased Expression of Placenta Growth Factor in Chronic Obstructive Pulmonary Disease

Shih-Lung Cheng 1, Hao-Chien Wang 1, Chong-Jen Yu 2* and Pan-Chyr Yang 2

1 Internal Medicine, Far Eastern Memorial Hospital, Taiwan
2 Internal Medicine, National Taiwan University Hospital, Taiwan

* To whom correspondence should be addressed. E-mail: jefferycjyu{at}ntu.edu.tw.

Accepted 21 November 2007


*   Abstract

Background: Vascular endothelial growth factor (VEGF) and its receptor may play an important role in the pathogenesis of emphysema. But the effect of another angiogenic factor, placenta growth factor (PlGF), to chronic obstructive pulmonary disease (COPD) is unknown.

Methods: We measured the levels of VEGF and PlGF in serum from patients with COPD (n=184), smokers (n=212), nonsmokers (n=159), and in bronchoalveolar lavage (BAL) fluid from another group (COPD n=20, controls n=18). In vitro cell culture experiments were performed to investigate the effect of PlGF on VEGF.

Results: The serum levels of PlGF were significantly higher in COPD than in controls (27.1 (SE, 7.4) pg/ml vs. 12.3 (SE, 5.1) pg/ml in smokers and 10.8 (SE, 6.3) pg/ml in nonsmokers, p=0.005). The levels of PlGF in BAL fluids were also significantly higher in COPD than in controls (45.7 (SE, 12.3) pg/ml vs. 23.9 (SE, 7.6) pg/ml, p=0.005), associated with an increase of all measured cytokines, like tumor necrosis factor-{alpha} (TNF-{alpha}) and interleukin-8 (IL-8). In COPD patients, the levels of PlGF correlated inversely with forced expiratory volume in one second (FEV1) (in serum, r=-0.59, p=0.002; and in BAL fluids, r=-0.51, p=0.001). While the levels of VEGF in serum were the same between COPD and controls, the levels in BAL fluids were significantly lower in COPD than in controls (127.5 (SE, 30.1) pg/ml vs. 237.8 (SE, 36.1) pg/ml, p=0.002). In cultured bronchial epithelial cells, proinflammatory cytokines induced an increase in the protein expression of both PlGF and VEGF. Continuous concomitant treatment with PlGF, TNF-{alpha} and IL-8 stimulation reduced VEGF expression and induced cell death. This phenomenon was suppressed by VEGF receptor inhibitor (CBO-P11).

Conclusions: PlGF was increased in serum and BAL fluids of COPD patients, and correlated inversely with FEV1. Concomitant treatment with PlGF, TNF-{alpha} and IL-8 generate detrimental effects on airway epithelial cells. These data suggest that bronchial epithelial cells can express PlGF which may contribute to the pathogenesis of COPD.


Keywords: chronic obstruction, placenta growth factor, pulmonary disease







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2008 BMJ Publishing Group Ltd & British Thoracic Society